Repligen Corporation (NASDAQ:RGEN) Shares Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 12.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,684 shares of the biotechnology company's stock after acquiring an additional 2,117 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Repligen were worth $2,505,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. purchased a new position in shares of Repligen during the fourth quarter worth $216,000. LPL Financial LLC grew its position in Repligen by 47.6% in the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after acquiring an additional 10,395 shares in the last quarter. Signaturefd LLC increased its stake in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the period. US Bancorp DE lifted its position in shares of Repligen by 1.9% during the fourth quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock worth $1,471,000 after purchasing an additional 190 shares in the last quarter. Finally, Zions Bancorporation N.A. boosted its stake in shares of Repligen by 48.9% in the fourth quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock valued at $2,027,000 after purchasing an additional 4,626 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of Repligen stock traded up $0.82 on Monday, hitting $124.38. The stock had a trading volume of 654,389 shares, compared to its average volume of 728,883. The company's 50 day moving average price is $127.95 and its 200 day moving average price is $140.60. The stock has a market cap of $6.99 billion, a price-to-earnings ratio of -276.40, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period in the prior year, the company earned $0.28 earnings per share. The company's revenue was up 10.4% compared to the same quarter last year. On average, research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on RGEN shares. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $172.83.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.